MX389626B - Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. - Google Patents

Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Info

Publication number
MX389626B
MX389626B MX2020004666A MX2020004666A MX389626B MX 389626 B MX389626 B MX 389626B MX 2020004666 A MX2020004666 A MX 2020004666A MX 2020004666 A MX2020004666 A MX 2020004666A MX 389626 B MX389626 B MX 389626B
Authority
MX
Mexico
Prior art keywords
treatment
formula
lipoic acid
eye disorders
crystals
Prior art date
Application number
MX2020004666A
Other languages
English (en)
Other versions
MX2020004666A (es
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2020004666A publication Critical patent/MX2020004666A/es
Publication of MX389626B publication Critical patent/MX389626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Aspectos de la presente divulgación proveen el compuesto de Fórmula I e hidratos, solvatos, cristales, co-cristales, enantiómeros, estereoisómeros, polimorfos y profármacos farmacéuticamenteaceptables de los mismos que pueden encontrar utilidad en el tratamiento de trastornos oculares y complicaciones asociadas con los mismos. Aspectos de la presente divulgación se relacionan con métodos para tratar un trastorno ocular y/o complicaciones del mismo en un sujeto en necesidad del mismo mediante la administración del compuesto de Fórmula I o un hidrato, solvato, cristal, enantiómero, estereoisómero, polimorfo y profármaco farmacéuticamente aceptables de los mismos. (Ver fórmula I) en donde, X+ representa, (Ver fórmula).
MX2020004666A 2017-11-17 2018-09-22 Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. MX389626B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741041231 2017-11-17
PCT/IB2018/057342 WO2019097318A1 (en) 2017-11-17 2018-09-22 Compositions and methods for the treatment of eye disorders

Publications (2)

Publication Number Publication Date
MX2020004666A MX2020004666A (es) 2022-01-26
MX389626B true MX389626B (es) 2025-03-20

Family

ID=66540065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004666A MX389626B (es) 2017-11-17 2018-09-22 Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Country Status (14)

Country Link
US (1) US10933052B2 (es)
EP (1) EP3651747A4 (es)
JP (1) JP7006990B2 (es)
KR (1) KR102349776B1 (es)
CN (1) CN111372576A (es)
AU (1) AU2018367909B2 (es)
BR (1) BR112020009361A2 (es)
CA (1) CA3081553C (es)
IL (1) IL274234B2 (es)
MX (1) MX389626B (es)
RU (1) RU2761436C1 (es)
SG (1) SG11202004019SA (es)
WO (1) WO2019097318A1 (es)
ZA (1) ZA202002066B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102442758B1 (ko) * 2016-10-04 2022-09-14 셀릭스 바이오 프라이빗 리미티드 구강건조증(xerostomia)의 치료를 위한 조성물 및 방법
SG11202004078YA (en) * 2017-11-17 2020-05-28 Cellix Bio Private Ltd Compounds, compositions and methods for treatment of eye disorders and skin diseases
WO2019150341A1 (en) * 2018-02-05 2019-08-08 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
MX2022006803A (es) * 2019-12-04 2022-09-19 Restore Vision Llc Formulaciones oftalmicas para el tratamiento de la presbicia.
TWI819268B (zh) * 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
WO2021240352A1 (en) * 2020-05-26 2021-12-02 Cellix Bio Private Limited Pharmaceutical formulations of pilocarpine r-(+)-lipoate
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
US20250101009A1 (en) * 2022-11-19 2025-03-27 Iview Therapeutics, Inc. Compounds, Compositions and Methods for Treatment of Age-Related Ocular Disorders
WO2025230326A1 (ko) * 2024-04-30 2025-11-06 주식회사태준제약 필로카르핀을 포함하는 점안 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50250A (en) 1975-08-27 1980-01-31 Hydrophilics Int Inc Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups
US4076942A (en) 1975-10-01 1978-02-28 Merck & Co., Inc. Crystalline dipilocarpinium pamoate
FR2424930A1 (fr) 1978-05-02 1979-11-30 Inst Khim Drevesiny Akadem Nouveaux polymeres d'alcoyl-1(oxo-5 alcoyl-4 tetrahydrofuryl-methyl(3)-5) imidazoles et d'ethers carboxyalcoyliques d'alcool polyvinylique, utiles notamment comme agents m-cholinomimetiques et leur procede de preparation
NL8800099A (nl) 1987-01-31 1988-08-16 Sandoz Ag Pilocarpinederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US4977176A (en) 1987-01-31 1990-12-11 Sandoz Ltd. Pilocarpine compounds which are used as pharmaceutical agents
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
JP2771257B2 (ja) 1989-06-22 1998-07-02 岩城製薬株式会社 イミダゾール誘導体の製法
US5322942A (en) 1991-06-03 1994-06-21 Regents Of The University Of California Synthesis of optically active lactones from L-aspartic acid and intermediates thereof
DE4222459C2 (de) 1992-07-08 1995-09-14 Sigma Tau Ind Farmaceuti 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
DE4334135A1 (de) 1993-10-07 1995-04-13 Merck Patent Gmbh Verfahren zur Herstellung von Pilocarpin-Derivaten
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
WO1997009315A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
KR19990076788A (ko) 1996-01-22 1999-10-15 후지야마 아키라 티아졸릴벤조푸란 유도체 및 그를 함유하는 약제학적 조성물
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6222039B1 (en) 1998-07-13 2001-04-24 Hoffman-La Roche Inc. Process for the preparation of chiral lactones
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
DE60226970D1 (de) 2001-06-05 2008-07-17 Lilly Icos Llc Pyrazinoä1',2':1,6ü-pyridoä3,4-bü indole-1,4-dionderivate
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
KR20050033070A (ko) 2002-08-09 2005-04-08 아스트라제네카 에이비이 메타보트로픽 글루타메이트 수용체-5의 조절제로서[1,2,4]옥사디아졸
WO2004026258A2 (en) 2002-09-19 2004-04-01 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
DE10358539A1 (de) 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
ZA200608176B (en) 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
CN101522658A (zh) 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8673970B2 (en) 2008-02-21 2014-03-18 Sequoia Pharmaceuticals, Inc. HIV protease inhibitor and cytochrome p450 inhibitor combinations
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
CN102099339A (zh) 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
US20110091459A1 (en) 2008-12-11 2011-04-21 Auspex Pharmaceuticals, Inc. Imidazole modulators of muscarinic acetylcholine receptor m3
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
EP3292868A1 (en) * 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
US9173886B2 (en) 2010-03-12 2015-11-03 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
CA2800401C (en) 2010-06-03 2020-09-15 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
CN103348243A (zh) 2010-11-30 2013-10-09 基因泰克公司 Lrrk2的分析方法和生物标记物
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
CN103582632B (zh) 2011-03-31 2015-08-19 拜耳知识产权有限责任公司 取代的苯并咪唑
US20140255392A1 (en) 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
JP2012230356A (ja) 2011-04-15 2012-11-22 Sumitomo Chemical Co Ltd 化合物、レジスト組成物及びレジストパターンの製造方法
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
US20140228384A1 (en) 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
HK1202543A1 (en) 2012-01-28 2015-10-02 Merck Patent Gmbh Azaheterocyclic compounds
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2014124141A1 (en) 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
WO2015018754A1 (en) 2013-08-08 2015-02-12 Boehringer Ingelheim International Gmbh Novel pyrazine amide compounds
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US20160317606A1 (en) 2014-01-06 2016-11-03 Stealth Bio Therapeutics Corp Methods and compositions for preventing or treating dominant optic atrophy
TN2016000567A1 (en) 2014-07-01 2018-04-04 Takeda Pharmaceuticals Co Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
CN104387364B (zh) 2014-12-15 2016-11-16 南京工业大学 L-鸟氨酸硫辛酸复合盐及其制备方法和应用
KR102442758B1 (ko) 2016-10-04 2022-09-14 셀릭스 바이오 프라이빗 리미티드 구강건조증(xerostomia)의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
JP7006990B2 (ja) 2022-02-10
AU2018367909A1 (en) 2020-05-07
IL274234B (en) 2022-10-01
CA3081553C (en) 2022-11-15
CA3081553A1 (en) 2019-05-23
EP3651747A1 (en) 2020-05-20
IL274234B2 (en) 2023-02-01
US20200179343A1 (en) 2020-06-11
CN111372576A (zh) 2020-07-03
ZA202002066B (en) 2021-07-28
BR112020009361A2 (pt) 2020-10-13
JP2021503449A (ja) 2021-02-12
WO2019097318A1 (en) 2019-05-23
IL274234A (en) 2020-06-30
AU2018367909B2 (en) 2022-03-10
EP3651747A4 (en) 2020-07-22
MX2020004666A (es) 2022-01-26
KR102349776B1 (ko) 2022-01-10
US10933052B2 (en) 2021-03-02
SG11202004019SA (en) 2020-05-28
RU2761436C1 (ru) 2021-12-08
NZ763688A (en) 2021-10-29
KR20200089292A (ko) 2020-07-24

Similar Documents

Publication Publication Date Title
MX389626B (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
ECSP21027049A (es) Inhibidores de la proteína tirosina fosfatasa
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
WO2016085939A3 (en) Compounds and methods of treating ocular disorders
CR20180168A (es) Derivados de heteroarilo como inhibidores de parp
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
PH12018502378A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2017003940A (es) Moduladores alostericos negativos de nr2b de n-alquilaril-5-oxiari l-octahidro-ciclopenta [c] pirrol.
NZ721645A (en) Compounds for use as gpr120 agonists
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
MX378160B (es) Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes.
CR20180443A (es) Derivado de morfolina
AR093042A1 (es) Derivados de etinilo
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
MX2020004667A (es) Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas.
AR097721A1 (es) Derivados de etinilo
CO6801735A2 (es) Derivados de pirazolidin-3-ona
MX390507B (es) Compuestos de amida y su uso.
AR104863A1 (es) Derivados imidazol